alexa
 
Home News Dishman Pharma zooms 20% as US FDA approves its cancer drug

Read more interesting news from around the globe with Wealth Doctor App

Google Play
 
Dishman Pharma zooms 20% as US FDA approves its cancer drug

Dishman Pharma zooms 20% as US FDA approves its cancer drug

Tuesday, March 28, 2017, 9:57 AM

Dishman Pharmaceutical & Chemicals in Tuesday's pre-opening session is sizzling on the bourses, and the stock is up by 20% at Rs.278.70, as the company received US FDA approved cancer drug, Zejula for Tesaro Inc. Dishman Pharmaceutical & Chemicals is one of the API suppliers of Zejula capsules. The stock hit its 52-week high of Rs 278.20, and is locked at its upper circuit.
Read More

Learn to Save, Spend, Invest & Borrow Wisely with our Youtube Channel

Get It now!